A share price of Amicus Therapeutics Inc [FOLD] is currently trading at $14.25, saw in change for the day. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FOLD shares have gain 30.85% over the last week, with a monthly amount glided 44.38%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on December 22, 2025, when TD Cowen downgraded its rating to a Hold but kept the price target unchanged to $14.50 for it. Previously, Citigroup started tracking the stock with Buy rating on December 17, 2025, and set its price target to $17. On September 18, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $14 on the stock. Morgan Stanley upgraded its rating to an Overweight but stick to its price target of $108 on July 17, 2025. Morgan Stanley downgraded its rating to an Equal-Weight and reduced its price target to $12 on December 13, 2024. Jefferies started tracking with a Buy rating for this stock on September 06, 2024, and assigned it a price target of $18. In a note dated May 30, 2024, Wells Fargo initiated an Overweight rating and provided a target price of $18 on this stock.
Amicus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.51 and $14.36. Currently, Wall Street analysts expect the stock to reach $14.25 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $14.25 at the most recent close of the market.
Analyzing the FOLD fundamentals
Trailing Twelve Months sales for Amicus Therapeutics Inc [NASDAQ:FOLD] were 598.70M which represents 19.46% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.01%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.1 and Total Capital is 0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.23 points at the first support level, and at 14.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.27, and for the 2nd resistance point, it is at 14.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Amicus Therapeutics Inc [NASDAQ:FOLD] is 2.99. As well, the Quick Ratio is 2.09, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 7.36, the price to book ratio is 19.08.
Transactions by insiders
Recent insider trading involved Clark David Michael, Chief People Officer, that happened on Dec 19 ’25 when 25642.0 shares were sold. Officer, DAVID CLARK completed a deal on Dec 19 ’25 to buy 25642.0 shares. Meanwhile, President and CEO Campbell Bradley L sold 77926.0 shares on Dec 15 ’25.
